GPCR Structure Corp: Price-to-Projected Revenue Ratio

Structure Therapeutics - graphic logo of issuer GPCR

Structure Therapeutics aims to commercialize innovative therapies for metabolic disorders. The development of oral GLP-1 analogs and the success of GSBR-129 create a powerful growth catalyst. The projected P/S ratio reflects these expectations, with the parameter reaching . However, current quotes largely front-run the actual financial impact of the upcoming clinical trials.

Structure Therapeutics Inc. - GPCR Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for Structure Corp (GPCR)

- market price and analyst price targets:
Price Chart Structure Therapeutics Inc.|GPCR - Average Forecast Price
- company stock capitalization data:
Market Value Structure Corp|GPCR - Total Company Value
- book value of equity indicators:
Book Value per Share Structure Therapeutics|GPCR - Book Valuation of Business|Market Value to Book Value Ratio structuretx.com|GPCR - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Structure Therapeutics|GPCR - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Structure Therapeutics|GPCR - Company Total Debt Obligations|Debt to Book Value Structure Corp|GPCR - Amount of Long-Term Liabilities|Company Short-Term Debt Structure Therapeutics|Quick Liquidity Indicator structuretx.com
- financial results and valuation multiples details:
GPCR - Net Profit|Projected Future Earnings Structure Therapeutics|GPCR - Price to Earnings Ratio|Projected Price to Earnings Structure Pharma|GPCR - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Structure Corp|GPCR - Operating profit EBITDA|Earnings per share for the last twelve months Structure Therapeutics|GPCR - Earnings per share for the trailing year|Quarterly EPS earnings growth structuretx.com|GPCR - Earnings per share growth rate in current year|Expected earnings per share growth for next year Structure Therapeutics
- sales volume and revenue indicators:
GPCR - Company Sales Revenue|Company Future Sales Volume Structure Therapeutics Inc.|GPCR - Market Cap to Sales Volume|Forward P/S Multiple Structure Corp
Comprehensive company analysis:Structure Therapeutics Inc. (GPCR)
Original product of Structure Therapeutics

Forward P/S is calculated as the ratio of current market capitalization to expected revenue for the next period. This multiple determines the premium paid per unit of future sales, identifying potential undervaluation or an overheated asset. For Structure Therapeutics (GPCR), with a current value of , the metric reflects market expectations for the commercialization of anti-obesity drugs. The trend of the organization's forward P/S allows for an assessment of the business's fair value during the clinical trial stage.

Competing companies

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Price-to-Projected Revenue Ratio Amicus Therapeutics FOLD|Market Cap to Expected Sales Ratio 89bio.com (ETNB)|AGIO: Forward Price-to-Revenue Multiple|MiMedx Group Inc - Price to Expected Revenue Ratio|Rezolute Corp (RZLT) - Price-to-Projected Revenue Ratio|Lexicon Corp - Forward Price to Sales|Forward Price-to-Revenue Multiple MBX|Forward P/S Multiple altimmune.com|Forward P/S Multiple AARD|Forward Price-to-Revenue Multiple Sagimet Biosciences, Inc. SGMT|BioAge Labs Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BMEA (Biomea Fusion Corp)|QNCX: Forward Price-to-Revenue Multiple|GUTS - Forward P/S Multiple|vtvtherapeutics.com (VTVT) - Price-to-Projected Revenue Ratio|Agape ATP - Forward Price to Sales|PLUR (Pluristem Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Synlogic Corp SYBX|Forward Price-to-Revenue Multiple LPCN (Lipocine Inc.)|MTNB (matinasbiopharma.com) - Forward Price to Sales|Spruce Biosciences, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio GLTO (Galecto Inc)|Carmell Corp - Forward P/S Multiple|Forward Price to Sales LUMO (Lumos Therapeutics)|ONVO: Forward P/S Multiple|Market Cap to Future Revenue Ratio radiuspharm.com (RDUS)